Dogwood Therapeutics (DWTX) Q4 Loss Narrows to $0.26, Beats Estimates
Dogwood Therapeutics posts Q4 loss of $0.26/share, 69.8% narrower than the $0.86 consensus, as clinical-stage biotech reduces burn...
Breaking market news, earnings coverage, and in-depth interviews with industry leaders.
Dogwood Therapeutics posts Q4 loss of $0.26/share, 69.8% narrower than the $0.86 consensus, as clinical-stage biotech reduces burn...
General Mills Q3 EPS of $0.64 missed estimates by 12.1% as strategic pricing investments weighed on results; management...
Star Equity posts Q4 loss of $0.10 per share, missing estimates by 152.6%, despite 69% revenue growth to...
Ovid Therapeutics swings to $0.06 EPS profit versus -$0.10 estimate, reversing year-ago loss with $9.7M net income on...
Giftify, Inc. (GIFT) reported Q4 2025 GAAP loss of $0.05 per share, a narrower loss than the -$0.06...
Weibo Corporation (WB) delivered Q4 2025 adjusted earnings of $0.25 per share, below analysts' $0.32 forecast (miss by...
CEO Adam Grossman sold 15,000 shares at $15.16, part of a broader pattern of net insider selling totaling...
CEO John Gregory Turner forfeited 16,130 shares at $13.60 for tax withholding, part of a six-month pattern showing...
Ulta Beauty CEO Kecia Steelman surrendered 1,491 shares at $535.72 in a tax withholding transaction, part of a...
CEO Peter Jackson and seven executives surrendered 31,470 shares worth $2.77M in tax withholdings, while insiders remain net...
Patrick E. Bowe sold 15,000 shares at $70.41, part of a six-month pattern showing 61,598 shares sold with...
VP & Treasurer Brian K. Walz sold 8,975 shares at $70.74, part of a six-month pattern of net...